Amarin guidance highlights continued Vascepa traction, says H.C. Wainwright Amarin's updated revenue guidance yesterday highlights the continued U.S. prescription traction of Vascepa, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst finds the guidance updates in line with his 100 physician survey, which suggests Amarin "remains in the early stages of Vascepa launch with significant upside ahead coinciding with growing physician awareness." Fein reiterates a Buy rating on the shares with a $51
price target.Read more at:
https://thefly.com/landingPageNews.php?id=2929191